Presentation of latest clinical data: Invitation to the scientific symposium
From 18th till 20th February 2009 the 19th Symposium of Intensive Care will take place in Bremen, Germany. We would like to turn your special attention to the symposium “Perspectives beyond protective ventilation” which will take place on Friday, 20th February 2009. As a press representative you are cordially invited to attend this symposium:
Invitation to the symposium „Perspectives beyond protective ventilation“:
Where: Fair and Congress Centre Bürgerweide, Bremen, Germany
When: Friday, 20th February 2009
9.00 am – 10.30 am
As mechanical ventilation is directly associated with a high mortality rate on the intensive care unit, the understanding of lung protecting ventilation, so called “protective” ventilation, has been broadly established in the intensive care medicine. But this can be exceeded! Innovative therapies such as the iLA Membrane Ventilator® or high frequency oscillatory ventilation allow a real lung protection which can go beyond current “protective” ventilation standards. Thus new therapy chances will be provided – for example for patients with an acute respiratory failure, an acute aggravation of a chronic pulmonary disease (so called exacerbated COPD) or for patients being in a prolonged weaning process from the mechanical ventilation.
New findings can increase survival rates
Through this symposium the participants will be informed on newest experiences in the application of these latest technologies. On the basis of actual clinical data and case studies the enabling therapy methods will be presented. Physician and nurses will learn about new therapy approaches which focus on healing and regeneration of the lung and therefore might improve patient’s outcome.
Worldwide reputable speakers
You can look forward to a very interesting morning with worldwide known speakers:
• Prof. Kuhlen (HELIOS Hospital Berlin-Buch, Germany) will present latest clinical user data of the iLA Membrane Ventilator® and
• Prof. Bein (University Hospital Regensburg, Germany) questions in his speech if a tidal volume of 6 ml/kg PBW is protective enough.
• Mrs. Dr. Rosseau (Charité Berlin, Germany) will discuss case studies regarding the therapeutically option for the iLA Membrane Ventilator® on hypercapnia insufficiency and
• Prof. Quintel (University Hospital Göttingen, Germany) will present the high frequency oscillatory ventilation as a further option for protective ventilation.
Early get up pays off!
For that you can attend this interesting symposium invigorated, we offer you at our booth B6 a delicious hangover breakfast at 8 am on Friday morning.
We are looking forward to your visit and the discussion with you during the intensive care congress in Bremen.
You can download high-resolution pictures as well as the literature compendium on www.novalung.com or it will be sent on request via email.
Please send us a copy of your imprint.
Background information Novalung GmbH - Driver of a paradigm shift
Novalung is the only company worldwide producing an artificial lung assist device – “Made in Germany” - which breathes outside the patient. The iLA Membrane Ventilator® eliminates the carbon dioxide outside the human lung driven by the human heart like a natural organ. Thereby the patient’s lung is protected as it doesn’t need to perform the complete gas exchange.
The iLA Membrane Ventilator® is implemented without surgery in a groin artery and vein by using two specifically developed NovaPort® vascular accesses. The artificial lung measures 14x14 cm only. Inside a hollow fibre membrane takes over the function of the pulmonary alveoli and completes the else wise common mechanical ventilation or can even replace it sometimes. Protective ventilation strategies can now be persecuted consequently; the natural lunge gets „time to heal“®. The iLA Membrane Ventilator® has been approved for a temporary use up to 29 days for patients of intensive care units.
In 2007 Novalung increased its portfolio by a high frequency oscillatory ventilator, Vision α®, being a quantum leap in mechanical ventilation. The high frequency oscillator focus on a very
protective and efficient oxygenation and enables therefore an optimal combination with the Membrane Ventilator® therapy.
Head of Marketing
Tel.: +49 7133 90 11 130
Fax: +49 7133 90 11 230
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Presentation of latest clinical data: Invitation to the scientific symposium here
News-ID: 67993 • Views: 1404
More Releases from Novalung GmbH
NovaPort twin, the Newest Double-Lumen Cannula, Approved
Novalung adds the unique double-lumen cannula to its expanding portfolio of products for the extrapulmonary treatment of lung failure. Now only a single cannula is required instead of two. Novalung announced today that it has received approval for the new NovaPort twin® double-lumen cannula, which is now available for clinical use. The NovaPort® twin cannula was specifically designed for veno-venous vascular access for the iLA activve® system - the Allrounder for
Novalung receives CE mark for iLA activve®
Novalung receives CE mark for iLA activve® With the new all-rounder for extrapulmonary lung support Novalung GmbH is the only company worldwide offering the complete portfolio for both pumpless and pump-driven lung support. Novalung announces receiving CE mark approval for their new pump-driven iLA activve® lung support system. It will be launched in Europe with immediate effect. Respiratory support with iLA activve® enables a treatment environment with awake, mobile patients instead
Novalung and Medos start cooperation
Due to the acquisition of Medos Medizintechnik AG by the private equity fund Zukunftsfonds Heilbronn (“Future Fund of Heilbronn”) the company will cooperate closely in the future with Novalung GmbH, which is expected to strengthen both medical device companies. The Zukunftsfonds Heilbronn (zfhn) announced that it has acquired Medos Medizintechnik AG from Ventizz Capital Partners Advisory AG. The purchase agreement was signed on January 7, 2011. With this
Josef Bogenschuetz joins Novalung as Managing Director
Novalung GmbH prepares for further growth with former Maquet CEO. As of January 1, 2011, Josef Bogenschütz and Dr. Georg Matheis are joint Managing Directors of Novalung GmbH. Bogenschütz will be specifically responsible for Research & Development, Manufacturing, Quality Management and Finance. This addition underscores the company’s focus on the ongoing and efficient expansion of its portfolio of innovative products designed to replace invasive mechanical ventilation. Nicholas L. Strout remains responsible
More Releases for Membrane
Membrane Bioreactor Market 2017-2023 | Key Players GE Water and Process Technolo …
The membrane bioreactor is the technology for wastewater treatment industries, which is witnessing greater adoption in the global market. The market includes the study of various types of configurations, products, applications and geographic analysis. The membrane bioreactor technology is more advanced than conventionally activated sludge method of wastewater management. The technology is efficient due to lower operational and maintenance cost. The market is driven due to increased utilization of the
Membrane Microfiltration Market 2018 - 2028 | By Membrane Type ( PES Membrane F …
Membrane Microfiltration Market: Value and Forecast The global membrane microfiltration market is expected to expand at a CAGR of 7.8% in revenue terms over the forecast period 2018–2028. The global membrane microfiltration market is expected to be dominated by Western Europe with a 22.3% revenue share in 2018. Membrane Microfiltration Market: Product Outlook In water treatment systems, microfiltration membranes help in removing small particles and solids such as iron (rust), manganese (rust), clay, silt and
Membrane Technology Market | Market Growth Analysis 2019
Transparency Market Research (TMR) has recently published a market study on the global membrane technology market, projecting the market to exhibit a CAGR of 9.10% during the period from 2014 to 2019 and reach a market value of US$10.8 bn by the end of the forecast period.The report, titled “Membrane Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019”, states that the worldwide membrane
Breathable Membrane Market : Industry Analysis 2024
Breathable membranes are semi-porous films or sheets, which allow the exchange of water vapor while preventing liquid water from permeating through. These membranes prevent water from seeping into the roof structure, while providing cold and warm ventilation. Breathable membranes are primarily used in the building & construction industry; they are used as underlay for various types of roofs such as slated pitched roofs and tiled roofs. Large amount of water
United States Photosensory Membrane Market Report 2017
Summary This report studies sales (consumption) of Photosensory Membrane in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering Company 1 Company 2 Company 3 Company 4 Company 5 Company 6 Company 7 Market Segment by States, covering California Texas New York Florida Illinois Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Split by applications, this report focuses on sales, market share
Global Membrane Switches Sales Market Report 2017
This report studies sales (consumption) of Membrane Switches in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Molex(US) XYMOX(US) Douglas Corporation(US) Fujikura(JP) Human E&C(KOR) Human E&C(KOR)